title: Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
abstract: Interleukin-10 (IL-10) is an immunosuppressive cytokine produced by T lymphocytes and drawing attention as an inhibitor of tumor angiogenesis. In this study, we investigated antiangiogenic and tumor suppressive effects of IL-10 in ovarian cancer cells. mIL-10-expressing plasmid was transferred into two ovarian cancer cell lines, SHIN-3 [vascular endothelial growth factor (VEGF) producing] and KOC-2S (non-VEGF producing). After selection, mIL-10-expressing cells were obtained as SHIN-3/mIL-10 and KOC-2S/mIL-10. No significant differences were observed in in vitro growth properties between mIL-10-expressing cells and control (luciferase expressing) cells in either KOC-2S or SHIN-3. The angiogenic activities of mIL-10-expressing cells were measured by dorsal air sac assay, which detected the number of newly formed blood vessels within a chamber in vivo. In addition, tumor formation was evaluated by s.c. tumor transplantation, and survival was monitored after i.p. injection of ovarian cancer cells into BALB/c nude mice. Both in vivo angiogenic activity and tumor growth were significantly inhibited in SHIN-3/mIL-10 cells compared with the control. Moreover, peritoneal dissemination was inhibited, and the survival period was significantly prolonged (mean survival days > 90 versus 36). In contrast, in the case of KOC-2S cells, no significant differences were observed in any of the parameters tested. These results indicate that IL-10 has suppressive effects on angiogenesis, tumor growth, and peritoneal dissemination of VEGF-producing ovarian cancer cells. Although the mechanisms of the antiangiogenic effect of IL-10 are still unclear, the potential usefulness of IL-10-mediated gene therapy of ovarian cancer was suggested.
authors.affiliation: Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi, 329-0498 Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kohno
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Mizukami
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Suzuki
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Saga
authors.forename: Yuji
authors.initials: Y
authors.lastname: Takei
authors.forename: Masahisa
authors.initials: M
authors.lastname: Shimpo
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsushita
authors.forename: Takashi
authors.initials: T
authors.lastname: Okada
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hanazono
authors.forename: Akihiro
authors.initials: A
authors.lastname: Kume
authors.forename: Ikuo
authors.initials: I
authors.lastname: Sato
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000818:Animals; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D016753:Interleukin-10 / Q000235:genetics* / Q000502:physiology; D008222:Lymphokines / Q000096:biosynthesis*; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000401:mortality / Q000628:therapy*; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016753:Interleukin-10